

HeidelbergCapital and Entrepreneurs Fund lead the takeover of the stake of EMBL Technology Fund in vasopharm GmbH

Juni 2013

HeidelbergCapital Private Equity, EF Investments S.à.r.l. (Entrepreneurs Fund), Bayern Kapital, Hanseatic Asset Management LBG, Dr. Andrew Clark, Chairman of the Supervisory Board, took over all shares of EMBL Technology Fund in Vasopharm GmbH for an undisclosed amount. The transaction was structured subsequent to the recent funding round where vasopharm raised sufficient new cash for preparation for clinical phase III.

HeidelbergCapital contributed significant amounts to the fund raising and the to the takeover. The company's lead compound VAS203 has met all clinical endpoints for safety and demonstrated strong evidence of clinical benefit in the Phase IIa European NOSTRA trial completed recently. VAS203 Phase II results demonstrated statistically significant improvements to both short term (Therapy Intensity Level) and long term (extended Glasgow Outcome Scale) measures of treatment efficacy. Data for pharmacokinetics, pharmacodynamics, metabolites and surrogate markers were compiled in the brain tissue by microdialysis during VAS203 treatment. Detailed results of the trial will be published soon in a peer-reviewed journal.

The company has applied for a scientific advice meeting with the European Medicines Agency (EMA). The response of EMA's Committee for Medicinal Products for Human Use (CHMP) is expected for the fourth quarter this year.

VAS203 has been granted orphan drug status for the treatment of moderate to severe TBI by the EMA.

P+P Partner Dr Michael Inhester, Munich provided legal advice to the purchaser